吡咯啉-5-羧酸还原酶-1在肿瘤中的作用及机制研究进展

doi:10.11904/j.issn.1002-3070.2023.03.012

Abstract

Abstract: Pyrroline-5-Carboxylate Reductase-1(PYCR1)is a key enzyme for synthesis of mitochondrial proline.More and more studies have shown that PYCR1 is highly expressed in various malignant tumors,affecting the biological behaviors such as tumor cell proliferation,apoptosis,invasion and migration,and is closely related to clinical prognosis.It is expected to become a new tumor biomarker,but its mechanism of action is relatively complex.This article will review the role of PYCR1 in tumorigenesis and development from three aspects: its mechanism of action,clinical significance and the effect of PYCR1 inhibitors on tumors.

Key words: PYCR1, Proline, Tumor, Mechanism of action

CLC Number:

R730.1

ZHOU Borong, SONG Yanan, XIA Wei. Research progress on the role and mechanism of pyrrolin-5-carboxylate reductase-1 in tumor[J]. Journal of Practical Oncology, 2023, 37(3): 267-271.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.03.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I3/267

References

1 Christensen EM,Patel SM,Korasick DA,et al.Resolving the cofactor-binding site in the proline biosynthetic enzyme human pyrroline-5-carboxylate reductase 1[J].J Biol Chem,2017,292(17):7233-7243.
2 D′Aniello C,Patriarca EJ,Phang JM,et al.Proline metabolism in tumor growth and metastatic progression[J].Front Oncol,2020,10:776.
3 Phang JM.Proline metabolism in cell regulation and cancer biology:Recent advances and hypotheses[J].Antioxid Redox Signal,2019,30(4):635-649.
4 Gao Y,Luo L,Xie Y,et al.PYCR1 knockdown inhibits the proliferation,migration,and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma[J].Mol Carcinog,2020,59(5):503-511.
5 Bogner AN,Stiers KM,Tanner JJ.Structure,biochemistry,and gene expression patterns of the proline biosynthetic enzyme pyrroline-5-carboxylate reductase(PYCR),an emerging cancer therapy target[J].Amino Acids,2021,53(12):1817-1834.
6 Bonnay F,Veloso A,Steinmann V,et al.Oxidative metabolism drives immortalization of neural stem cells during tumorigenesis[J].Cell,2020,182(6):1490-1507.
7 Liu W,Hancock CN,Fischer JW,et al.Proline biosynthesis augments tumor cell growth and aerobic glycolysis:involvement of pyridine nucleotides[J].Sci Rep.2015,5:17206.
8 Westbrook RL,Bridges E,Roberts J,et al.Proline synthesis through PYCR1 is required to support cancer cell proliferation and survival in oxygen-limiting conditions[J].Cell Rep,2022,38(5):110320.
9 Oudaert I,Satilmis H,Vlummens P,et al.Pyrroline-5-carboxylate reductase 1:a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis[J].J Exp Clin Cancer Res,2022,41(1):45.
10 Chen K,Guo L,Wu C.How signaling pathways link extracellular mechano-environment to proline biosynthesis:A hypothesis:PINCH-1 and kindlin-2 sense mechanical signals from extracellular matrix and link them to proline biosynthesis[J].Bioessays,2021,43(9):e2100116.
11 Zhang J,Shang L,Jiang W,et al.Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells[J].Bioengineered,2022,13(3):7904-7918.
12 Guo J,Cheng X,Tian Y,et al.Knockdown of PYCR1 suppressed the malignant phenotype of human hepatocellular carcinoma cells via inhibiting the AKT pathway activation[J].Reprod Biol,2021,21(3):100534.
13 Xiao S,Li S,Yuan Z,et al.Pyrroline-5-carboxylate reductase 1(PYCR1)upregulation contributes to gastric cancer progression and indicates poor survival outcome[J].Ann Transl Med,2020,8(15):937.
14 Du S,Sui Y,Ren W,et al.PYCR1 promotes bladder cancer by affecting the Akt/Wnt/β-catenin signaling[J].J Bioenerg Biomembr,2021,53(2):247-258.
15 Cheng C,Song D,Wu Y,et al.RAC3 promotes proliferation,migration and invasion via PYCR1/JAK/STAT signaling in bladder cancer[J].Front Mol Biosci,2020,7:218.
16 Yan K,Xu X,Wu T,et al.Knockdown of PYCR1 inhibits proliferation,drug resistance and EMT in colorectal cancer cells by regulating STAT3-Mediated p38 MAPK and NF-κB signalling pathway[J].Biochem Biophys Res Commun,2019,520(2):486-491.
17 Wei X,Zhang X,Wang S,et al.PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma[J].Am J Cancer Res,2022,12(8):3780-3798.
18 Li H,Ning S,Ghandi M,et al.The landscape of cancer cell line metabolism[J].Nat Med,2019,25(5):850-860.
19 Xiao S,Yao X,Ye J,et al.Epigenetic modification facilitates proline synthase PYCR1 aberrant expression in gastric cancer[J].Biochim Biophys Acta Gene Regul Mech,2022,1865(6):194829.
20 Song W,Yang K,Luo J,et al.Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression[J].Aging(Albany NY),2021,13(3):3909-3925.
21 Chen S,Yang X,Yu M,et al.SIRT3 regulates cancer cell proliferation through deacetylation of PYCR1 in proline metabolism[J].Neoplasia,2019,21(7):665-675.
22 Guo L,Cui C,Wang J,et al.PINCH-1 regulates mitochondrial dynamics to promote proline synthesis and tumor growth[J].Nat Commun,2020,11(1):4913.
23 Phang JM,Liu W,Hancock CN,et al.Proline metabolism and cancer:emerging links to glutamine and collagen[J].Curr Opin Clin Nutr Metab Care,2015,18(1):71-77.
24 Kuo CL,Chou HY,Chiu YC,et al.Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis[J].Cancer Lett,2020,474:138-150.
25 Xu Y,Zuo W,Wang X,et al.Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma[J].Int J Biol Sci,2021,17(9):2223-2239.
26 Wang H,Mao W,Lou W,et al.PYCR1:A potential prognostic biomarker in pancreatic ductal adenocarcinoma[J].J Cancer,2022,13(5):1501-1511.
27 Liu Z,Sun T,Zhang Z,et al.An 18-gene signature based on glucose metabolism and DNA methylation improves prognostic prediction for urinary bladder cancer[J].Genomics,2021,113(1 Pt 2):896-907.
28 She Y,Mao A,Li F,et al.P5CR1 protein expression and the effect of gene-silencing on lung adenocarcinoma[J].PeerJ,2019,7:e6934.
29 Shenoy A,Belugali Nataraj N,Perry G,et al.Proteomic patterns associated with response to breast cancer neoadjuvant treatment[J].Mol Syst Biol,2020,16(9):e9443.
30 Liu W,Wang Q,Chang J.Global metabolomic profiling of trastuzumab resistant gastric cancer cells reveals major metabolic pathways and metabolic signatures based on UHPLC-Q exactive-MS/MS[J].RSC Adv,2019,9(70):41192-41208.
31 Wu Y,Zhang X,Wei X,et al.A mitochondrial dysfunction and oxidative stress pathway-based prognostic signature for clear cell renal cell carcinoma[J].Oxid Med Cell Longev,2021,2021:9939331.
32 Zhou B,Mai Z,Ye Y,et al.The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer[J].Hum Cell,2022,35(6):1900-1911.
33 Milne K,Sun J,Zaal EA,et al.A fragment-like approach to PYCR1 inhibition[J].Bioorg Med Chem Lett,2019,29(18):2626-2631.
34 Christensen EM,Bogner AN,Vandekeere A,et al.In crystallo screening for proline analog inhibitors of the proline cycle enzyme PYCR1[J].J Biol Chem,2020,295(52):18316-18327.
35 Forlani G,Sabbioni G,Ragno D,et al.Phenyl-substituted aminomethylene-bisphosphonates inhibit human P5C reductase and show antiproliferative activity against proline-hyperproducing tumour cells[J].J Enzyme Inhib Med Chem,2021,36(1):1248-1257.

[1]	ZHONG Xuejin, WU Chunmei, LI Qiuyan, ZENG Tao. Research progress of Kin 17 in tumors [J]. Journal of Practical Oncology, 2023, 37(3): 272-275.
[2]	YIN Dingwei, JING Jie. Research progress on the role of Gut microbiota in hepatocellular carcinoma and its therapeutic application [J]. Journal of Practical Oncology, 2023, 37(3): 281-286.
[3]	LIU Xinxin, MA Xiyuan, MIU Meiqi, WANG Yuqing, CHEN Jing. Research progress on the role of IL-6 and its receptor in the treatment of breast cancer [J]. Journal of Practical Oncology, 2023, 37(2): 149-154.
[4]	YANG Jianhua, LUO Saimei, LONG Xintian, LI Wei, YANG Birong, YU Longtao, ZHANG Teng, WEN Hongmei. Analyses of incidence and mortality of malignant tumors in cancer registration areas of Yunnan province in 2017 [J]. Journal of Practical Oncology, 2023, 37(1): 6-10.
[5]	MA Jixiong, MA Juhong, ZHUO Hong, LU Zhaoxia, DING Gaoheng, LIU Yuqin. Incidence and mortality of malignant tumors of Baiyin in Gansu province,2018 [J]. Journal of Practical Oncology, 2023, 37(1): 11-16.
[6]	CAI Qirui, YU Xiaolan, LIU Jiaren. Research progress on antitumor activity and other biological effects of geraniol [J]. Journal of Practical Oncology, 2023, 37(1): 58-62.
[7]	LI Shuzhen, CAI Zhifu, RONG Yan, PANG Yebin, LUO Dongni, GAO Kun. Research progress of tumor volume in cervical cancer brachytherapy [J]. Journal of Practical Oncology, 2023, 37(1): 63-67.
[8]	ZHU Xing, ZHANG Bing, ZHAO Jing, JI Hong. Research progress on the role and mechanism of ferroptosis in urinary neoplasms [J]. Journal of Practical Oncology, 2023, 37(1): 73-78.
[9]	CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies [J]. Journal of Practical Oncology, 2022, 36(6): 507-512.
[10]	ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy [J]. Journal of Practical Oncology, 2022, 36(6): 513-519.
[11]	NA Ruisi, GUO Ying, SHI Jiaqi, ZHENG Tongsen. Reasons why small intestinal tunors are rare [J]. Journal of Practical Oncology, 2022, 36(6): 526-530.
[12]	WANG Xinyi, LU Yiping, SUN Zhengrong. Research progress on the effects of m6A RNA methylation modification on the biological characteristics of malignant tumors and tumor stem cells [J]. Journal of Practical Oncology, 2022, 36(6): 551-555.
[13]	ZHANG Shumin, ZHANG Gong. Research progress of ILC2s in tumor immune regulation [J]. Journal of Practical Oncology, 2022, 36(6): 566-569.
[14]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.
[15]	WANG Qin, LIU Junjie, LU Xiuxin, WU Yafei, ZHANG Wenhao. Research progress of nanocombination therapy based on ferroptosis in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(5): 429-434.

Research progress on the role and mechanism of pyrrolin-5-carboxylate reductase-1 in tumor

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments